Regeneron PharmaceuticalsREGN
About: Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Employees: 15,106
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2% more call options, than puts
Call options by funds: $1.19B | Put options by funds: $1.17B
0.93% more ownership
Funds ownership: 85.11% [Q3] → 86.04% (+0.93%) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 473 | Existing positions reduced: 481
6% less funds holding
Funds holding: 1,366 [Q3] → 1,287 (-79) [Q4]
23% less first-time investments, than exits
New positions opened: 163 | Existing positions closed: 211
31% less capital invested
Capital invested by funds: $95.9B [Q3] → $66.3B (-$29.6B) [Q4]
39% less funds holding in top 10
Funds holding in top 10: 23 [Q3] → 14 (-9) [Q4]
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Canaccord Genuity John Newman 12% 1-year accuracy 3 / 26 met price target | 73%downside $150 | Hold Maintained | 17 Apr 2025 |
B of A Securities Tim Anderson 40% 1-year accuracy 6 / 15 met price target | 3%downside $547 | Underperform Maintained | 17 Apr 2025 |
Goldman Sachs Salveen Richter 11% 1-year accuracy 2 / 18 met price target | 63%upside $917 | Buy Maintained | 14 Apr 2025 |
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target | 78%upside $1,000 | Overweight Maintained | 31 Mar 2025 |
Baird Brian Skorney 27% 1-year accuracy 6 / 22 met price target | 35%upside $759 | Neutral Maintained | 5 Feb 2025 |
Financial journalist opinion
Based on 22 articles about REGN published over the past 30 days
